Background: Several cluster-randomized trials are underway to investigate the implementation and effectiveness of a universal test-and-treat strategy on the HIV epidemic in sub-Saharan Africa. We consider nesting studies of pre-exposure prophylaxis within these trials. Pre-exposure prophylaxis is a general strategy where high-risk HIV-persons take antiretrovirals daily to reduce their risk of infection from exposure to HIV. We address how to target pre-exposure prophylaxis to high-risk groups and how to maximize power to detect the individual and combined effects of universal test-and-treat and pre-exposure prophylaxis strategies. Methods: We simulated 1000 trials, each consisting of 32 villages with 200 individuals per village. At baseline, we randomized the universal test-and-treat strategy. Then, after 3 years of follow-up, we considered four strategies for targeting pre-exposure prophylaxis: (1) all HIV-individuals who self-identify as high risk, (2) all HIV-individuals who are identified by their HIV + partner (serodiscordant couples), (3) highly connected HIV-individuals, and (4) the HIV-contacts of a newly diagnosed HIV + individual (a ring-based strategy). We explored two possible trial designs, and all villages were followed for a total of 7 years. For each village in a trial, we used a stochastic block model to generate bipartite (malefemale) networks and simulated an agent-based epidemic process on these networks. We estimated the individual and combined intervention effects with a novel targeted maximum likelihood estimator, which used cross-validation to dataadaptively select from a pre-specified library the candidate estimator that maximized the efficiency of the analysis. Results: The universal test-and-treat strategy reduced the 3-year cumulative HIV incidence by 4.0% on average. The impact of each pre-exposure prophylaxis strategy on the 4-year cumulative HIV incidence varied by the coverage of the universal test-and-treat strategy with lower coverage resulting in a larger impact of pre-exposure prophylaxis. Offering pre-exposure prophylaxis to serodiscordant couples resulted in the largest reductions in HIV incidence (2% reduction), and the ring-based strategy had little impact (0% reduction). The joint effect was larger than either individual effect with reductions in the 7-year incidence ranging from 4.5% to 8.8%. Targeted maximum likelihood estimation, data-adaptively adjusting for baseline covariates, substantially improved power over the unadjusted analysis, while maintaining nominal confidence interval coverage. Conclusion: Our simulation study suggests that nesting a pre-exposure prophylaxis study within an ongoing trial can lead to combined intervention effects greater than those of universal test-and-treat alone and can provide information about the efficacy of pre-exposure prophylaxis in the presence of high coverage of treatment for HIV + persons.
Introduction
Despite the ongoing scale-up of antiretroviral therapy, an estimated 2 million people became infected with HIV and 1.2 million died of AIDS-related illnesses in 2014. 1 Mounting evidence suggests that early HIV diagnosis combined with immediate antiretroviral therapy could slow the spread of HIV. 2, 3 In particular, the TEMPRANO and START trials reported that early treatment initiation (regardless of disease stage) resulted in improved health outcomes for HIV + people. 4, 5 Furthermore, the HPTN052 study confirmed that sustained antiretroviral therapy sharply reduces the risk of HIV transmission between serodiscordant couples. 6 Synthesizing these data with prior studies, the WHO recently recommended antiretroviral therapy for all persons living with HIV regardless of clinical stage and at all CD4 levels. 3 These recommendations are in line with the UNAIDS 90-90-90 cascade target: 90% of all HIV + people know their status, 90% of those with known HIV + status are on sustained antiretroviral therapy, and 90% of those on antiretroviral therapy are virally suppressed. 7 Both organizations are calling for implementation of a universal test-and-treat strategy: early HIV diagnosis and immediate antiretroviral therapy initiation for all HIV + people. Such a strategy is expected to not only preserve the health of HIV + people but also protect their partners and children. [4] [5] [6] 8, 9 At the time of the WHO and UNAIDS guidelines, four cluster-randomized trials were underway to investigate the population-level impact of universal test-andtreat. Specifically, the ANRS12249 TasP trial is ongoing in South Africa (NCT01509508), 10 the BCPP trial in Botswana (NCT01965470), 11 the HPTN071 PopART trial in South Africa and Zambia (NCT01900977), 12 and the SEARCH trial in Uganda and Kenya (NCT01864603). 13 These studies are cluster-randomized trials, wherein the units of randomization are communities or villages. The primary outcome of HIV incidence captures not only the direct effect of the intervention at the individual-level but also indirect and spillover effects among individuals within a cluster.
In light of the recent recommendations, several questions arise regarding the relevance and power of these studies. These trials will provide estimates of the population-level effect of universal test-and-treat on HIV incidence as well as other health, economic, and educational outcomes. Furthermore, these trials will provide information on how best to implement universal test-and-treat in resource-limited settings as well as guidance on the feasibility and sustainability of the strategy in diverse contexts. However, as countries embrace the new WHO guidelines, the control arm for each of these trials will more closely resemble the intervention arm. This change in standard of care will attenuate the randomized effects and threaten statistical power. Finally, it is unknown whether universal test-and-treat alone is sufficient; once the UNAIDS 90-90-90 target has been reached, what other strategies will be needed to achieve zero new infections?
In this article, we consider adding targeted preexposure prophylaxis (PrEP) to an ongoing test-andtreat trial. PrEP refers to the provision of antiretroviral therapy to high-risk HIV people to reduce risk of infection from exposure to HIV. Recent studies have indicated that PrEP can sharply reduce HIV transmission when taken regularly. [14] [15] [16] [17] Formal evaluation of PrEP in the context of universal test-and-treat is especially pressing given the WHO guidelines, recommending PrEP as an ''additional prevention choice for people at 'substantial risk'.'' 3 Using a network-based approach to simulation, we consider (1) targeting PrEP to people at substantial risk, (2) the impact of adding a targeted PrEP strategy to an ongoing cluster-randomized trial, and (3) the best design and analysis to maximize power to detect the individual and joint effects of test-andtreat and PrEP.
Methods

Targeted PrEP strategies
Ideal candidates for PrEP are HIV-individuals who are at high risk of acquiring HIV. We consider four strategies for targeting PrEP:
On-demand: HIV-individuals who self-identify as being high risk Couples: HIV-individuals who are identified by their HIV + partner Degree: HIV-individuals who report having 2 + partners Ring: HIV-partners of a newly diagnosed HIV + individual.
The feasibility, cost, and acceptability of each strategy will vary by epidemiological context. On-demand PrEP relies on measuring demographic characteristics and providing PrEP education to these key populations or vulnerable groups (e.g. young women 18 ). As a result, implementation of On-demand PrEP may not require any additional data collection but may be poorly targeted. There is strong evidence that Couples PrEP reduces the HIV transmission when adherence is high. [14] [15] [16] [17] This strategy could be implemented, for example, in the SEARCH trial where serodiscordant couples are identified through annual communitybased testing programs. 19, 20 Degree PrEP is in line with the 2014 Clinical Practice Guidelines 21 and also relies on self-report. Misreporting the number of sexual partners could result in poor targeting. Ring PrEP is inspired by the recent success of the vaccine effectiveness trial against Ebola Virus Disease in Guinea. 22 This approach requires contact tracing or identification (at least in part) of the underlying sexual networks. 23 Both Couples and Ring PrEP are expected to have the greatest impact if the index case is detected during the acute and early phases of infection when transmission rates are the highest. 24 As a result, these targeting strategies fit well within ongoing test-and-treat trials, where population-wide testing is regularly occurring. 19, 20 Trial design
To investigate the impact of each PrEP strategy, we simulate 1000 cluster-randomized trials. In each trial, there are 32 villages (experimental units) with 200 individuals each. At baseline the test-and-treat assignment is randomized among villages with balanced allocation: 16 intervention and 16 control. We parameterize coverage as the proportion of village members who would successfully complete the care cascade (testing, treatment, retention, and adherence) for antiretroviral therapy or PrEP, as appropriate. The test-and-treat intervention provides universal eligibility for antiretroviral therapy at a high coverage: 85% of HIV + patients on treatment and suppressed. To capture the evolving landscape of HIV prevention and to reflect baseline trial data, 3, [25] [26] [27] the test-and-treat control arm also provides universal eligibility for antiretroviral therapy, but with lower coverage: 55% of HIV + patients on treatment and suppressed.
After 3 years of follow-up, we modify the trial to account for uptake of the WHO guidelines. 3 Specifically, we consider a second randomization to investigate the effect of a targeted PrEP strategy versus the standard of care. We explore two trial designs: Design 1 randomizes a given PrEP strategy within the test-and-treat intervention arm (8 targeted PrEP and 8 standard of care, total); Design 2 ramps up coverage of antiretroviral therapy in the test-and-treat control arm from 55% to 85% and randomizes the PrEP strategy within each test-and-treat trial arm separately (16 targeted PrEP and 16 standard of care, total). In both designs, we assume high coverage in the PrEP intervention arm: 85% of all individuals who are eligible under a given strategy are on PrEP and adherent. To reflect the ongoing trials, the standard of care for PrEP is 0% coverage. If in the future PrEP were regularly offered, the control arm as the standard of care would reflect this change in eligibility and therefore coverage. This complexity, however, is ignored here. All villages are followed for 4 additional years after the second randomization.
Designs 1 and 2 are shown in Figures 1 and 2 , respectively. The first design might be favored when resources prohibit simultaneous scale-up of both antiretroviral therapy and PrEP. The latter design reflects the recent modifications to the SEARCH trial. * 28 Both designs constitute a sequentially randomized trial, wherein the units (villages) are randomized first at baseline and subsequently at follow-up year 3. Unlike a sequential multiple assignment randomized trial, 29 however, the second randomization is not adaptive-it does not depend on the outcomes in the first phase. Design 2 is similar to a 2 3 2 factorial design; 30, 31 all the relevant combinations of the treatment are present and the effect of individual components and their interactions can be examined. However, unlike a standard factorial design, the second experimental condition (PrEP) is introduced part way through the trial.
Network generation
For each village in a trial, we generate an underlying sexual network with a degree-corrected, bipartite (female/male) stochastic block model. 32 Each the universal test-and-treat (UTT) assignment (high vs lower coverage) is randomized with balanced allocation to the 32 villages. After 3 years of follow-up, the coverage of antiretroviral therapy is scaled-up in the UTT control arm (from low to high coverage), and the PrEP assignment (high vs no coverage) is randomized within both UTT arms separately. All villages are followed for 4 additional years after the second randomization.
*We note SEARCH is a pair-matched, two-phase trial with six years of total follow-up. individual (node) has an expected number of partners (degree) and belongs to a block. An individual's degree is distributed according to a powerlaw with exponent 2.5. Block structure represents the sexual mixing patterns among discrete demographic groups. The probability of a connection (edge) between two individuals depends on their expected number of partners and their probabilities of connecting within or across blocks. Our structure is specified to create three blocks where relationships mainly occur within block pairs, and two blocks that mix heavily with others. A schematic representation of the block matrix and the mixing diagram are shown in Figure 3 , and further details are provided in the Supplementary Material.
Epidemic dynamics
For each village in a trial, we simulate an infectious spread on the network with a susceptible-infectedrecovered compartmental model. 33 We select time steps of 1 year to aid in interpretation. At each time step, an HIV + individual could infect each of his/her susceptible partners (degree infectivity). The probability of transmission depends on the infectiousness of the HIV + individual and the susceptibility of his/her HIV-partner. We model the probability that an HIV + individual is in the acute phase and thereby highly infectious 24 with an independent Bernoulli process. We assume antiretroviral therapy reduces the risk of an HIV + individuals infecting others at each time step by 90%. 6 We also assume that 10% of the HIV + population have a low viral load without treatment and their risk of infecting others is reduced by 90%. [34] [35] [36] Finally, we assume high adherence to PrEP, reducing susceptibility by 90% in both men and women in heterosexual relationships. [14] [15] [16] [17] To initiate the epidemic, we randomly select 10% of village members to be infected. The infectious process then spreads until reaching an average pre-trial prevalence of 25%. We then begin the trial and generate the counterfactual outcomes under the treatment arms (described above). We also include a time-lag between treatment eligibility and uptake with an independent Bernoulli process. To reflect ongoing HIV prevention and treatment efforts, 55% of HIV + individuals are assumed to be on antiretroviral therapy and suppressed prior to the study start. [25] [26] [27] Full Python code to generate networks and simulate the epidemic are given in Staples. 37 
Causal effects
Let A1 be an indicator of the first randomized assignment with A1 = 1 for universal test-and-treat with high coverage and A1 = 0 for universal test-and-treat with lower coverage. Similarly, let A2 indicate the second randomization with A2 = 1 for PrEP with high coverage and A2 = 0 for standard of care PrEP. We denote the joint treatment assignment as A = (A1, A2). As outlined in Table 1 , the proposed trials allow for effect estimation of various treatment combinations.
First, we can estimate the effect of test-and-treat with high coverage (A1 = 1) compared to lower coverage (A1 = 0) on the 3-year cumulative HIV incidence from study start to year 3. This ''universal test-andtreat before PrEP'' effect estimate is based on all 32 villages. We can also estimate the effect of a given PrEP strategy with high and sustained coverage of test-andtreat on the 4-year cumulative incidence from study year 3 to study termination. This comparison utilizes 16 villages: 8 intervention A = (1, 1) and 8 control A = (1, 0). Within Design 2, we can estimate the PrEP effect with initially lower and then scaled-up coverage of test-and-treat on the 4-year cumulative incidence; this comparison utilizes 16 villages: 8 intervention A = (0, 1) and 8 control A = (0, 0). Also within Design 2, we can estimate the ''main'' 30, 31 PrEP effect on the 4-year incidence. This is the effect of targeted PrEP versus the standard of care averaging over the test-andtreat arms and utilizes all 32 villages: 16 intervention A2 = 1 and 16 control A2 = 0. We can estimate the analogous test-and-treat effects (within and collapsing over PrEP arms) on the 7-year cumulative incidence. Finally, with both designs, we can estimate the joint effect of high coverage of both test-and-treat and PrEP A = (1, 1) versus (initially) low coverage of test-andtreat A = (0, 0) on the 7-year incidence.
We define these effects as contrasts between counterfactual outcomes. 38, 39 Let A Ã be the treatment indicator, equaling 1 for the relevant intervention combination and 0 for the relevant control combination. For example, for the PrEP effect within the test-and-treat intervention arm, A Ã would equal 1 for high coverage of both test-and-treat and PrEP and 0 for high coverage of only test-and-treat. Furthermore, let Y k (a Ã ) represent the counterfactual cumulative incidence that would have been observed for village k if possibly contrary-tofact the village received treatment combination A Ã = a Ã . The average difference in these counterfactual outcomes captures the effects of interest. We focus on the sample average treatment effect [40] [41] [42] [43] [44] [45] 
Estimation and inference
Since our design is a two-phase randomized trial, the unadjusted estimator-the difference in the average outcomes among intervention units and the average outcomes among control units-provides an unbiased estimate of the treatment effect Unadj: =
where k = f1, . . . , Kg indexes the villages with the relevant treatment combinations. When baseline characteristics predict the outcome, this simple difference-in-means estimator can be inefficient as it fails to adjust for measured covariates. In general, adjusting for baseline covariates during the analysis can reduce variance without creating bias, even in small trials. [46] [47] [48] [49] [50] [51] We compare the unadjusted estimator with targeted maximum likelihood estimation (TMLE), a general method for the construction of double robust, semiparametric, efficient substitution estimators. 39, 45 Briefly, the algorithm updates an initial estimator of the expected outcome, given the treatment assignment and covariates E(Y jA Ã , W ), with information in the known or estimated treatment mechanism P(A Ã jW ). This targeting step is used to achieve the optimal biasvariance trade-off for the parameter of interest and to solve the efficient score equation. A point estimate is given by the average difference in the targeted predictions
where again k = f1, . . . , Kg indexes the villages with the relevant treatment combinations and wherê E Ã (Y jA Ã , W ). denotes a targeted estimate of the conditional mean outcome. With few independent units (villages), we are limited to the size of the adjustment set (i.e. variables included in the outcome regression or in estimation of the known treatment mechanism). Therefore, we apply the targeted maximum likelihood estimator described in Balzer et al. 52 to select from a pre-specified library the candidate estimator that maximizes precision. We consider the following individual-level candidate adjustment variables
Nothing Demographic risk group: indicator of belonging to the high-risk block Degree: number of partners Number of partners (network neighbors) infected at baseline
We also include the following village-level candidate adjustment variables:
Village HIV prevalence at baseline Assortativity: degree-degree correlation taken over all network connections (edges) Number of components: number of distinct groups with no connections (edges) between members of different groups Here, ''baseline'' refers to study year 0 for the testand-treat and joint effects and to study year 3 for the PrEP effects. Our candidates include a mix of variables that are fairly easy to collect (demography, degree, village prevalence), are more difficult (number of partners infected, assortativity), and possibly unknowable (number of components). We note that measurement of a full sexual 23 or social 13 contact network would allow for adjustment for potentially very predictive covariates. 53, 54 Both the unadjusted estimator and the targeted estimator are asymptotically linear; their limiting distributions are normal with mean zero and variance given by the variance of their influence curves (section 4.2 of Balzer et al. 45 ). To account for limited numbers of independent units in these simulations, Student's t-distribution is used in place of the standard normal 28, 55, 56 when constructing Wald-type 95% confidence intervals and testing the null hypothesis of no average effect for the study units. To the best of our knowledge, this is the first application of the hierarchical targeted maximum likelihood estimator, proposed in Balzer et al. 57 to make full use of individual-level data when estimating the cluster-level effect. Further details are given in the Supplementary Material, and full R code is available in Balzer. 58
Results
Our main simulation results are summarized in Table 2 . We focus on the test-and-treat effect before PrEP, the PrEP effects, and the joint effect. Additional results are given in the Supplementary Material. For each effect, we show the average cumulative HIV incidence for each intervention and control scenario and the average value of the sample effect across 1000 simulated trials. For estimator performance, we give the mean-squared error, the 95% confidence interval coverage, and the attained power. For simplicity, we only present the results from Design 1 if they differ meaningfully from Design 2.
The test-and-treat intervention reduces the cumulative incidence in the first 3 years of the trial by 4.0% on average. We have 76% power to detect this effect with the unadjusted estimator and 95% power with the targeted estimator using adaptive pre-specification to select the adjustment set for the outcome regression E(Y jA Ã , W ) and treatment mechanism P(A Ã jW ). In this case, the number of partners infected at baseline is selected as the adjustment variable for the outcome regression in 82% of the trials ( Supplementary  Table 1 ). Through adjustment, targeted estimation improves performance by reducing the estimator's variability (smaller mean squared error) and by providing a less-conservative variance estimator 45 and hence higher power.
For Design 2, the impact of a given PrEP strategy on the 4-year incidence varies by the test-and-treat arm. Initially, lower antiretroviral therapy coverage results in a larger impact of each PrEP strategy. For example, Couples PrEP results, on average, in a 1.7% reduction in incidence in the test-and-treat intervention arm where antiretroviral therapy coverage is always at 85%, and in a 2% reduction in the test-and-treat control arm where antiretroviral therapy coverage is initially at 55% and then ramps up to 85%. Consistently, the largest impact is with Couples PrEP, and there is no impact of Ring PrEP in these simulations. These results are robust to the assumed coverage of antiretroviral therapy and PrEP (Supplementary Figure 1) . We further note that in these simulations, the Couples strategy requires the largest person-years on PrEP, and the Ring strategy fails to put high-risk individuals on PrEP (Supplementary Figure 1) .
For these effects, the targeted estimator is slightly more variable than the unadjusted (larger mean-squared error) possibly due to a large library for data-adaptive estimation and only 16 independent units. Nonetheless, the targeted estimator still results in slightly more power. The number of partners infected and the village HIV prevalence at baseline (here, year 3) are selected for adjustment in '48% and '13% of the trials, respectively. This suggests that including time-updated covariates in the candidate adjustment set is important to maximize power to detect the PrEP effects.
For the main effect of PrEP on the 4-year incidence, the largest impact is associated with the Couples strategy (-1.9% on average), followed by the Degree strategy (-1.4% on average), the On-demand strategy (-0.6% on average), and finally, the Ring strategy (0% on average). As noted above, the main PrEP effect is the impact of a given strategy averaged over the testand-treat arms. For these effects, improved performance with targeted estimation is demonstrated by smaller mean-squared errors and higher power. For example, to detect the main effect of Couples PrEP, the unadjusted approach provides 83% power and targeted estimation 90%. For these effects, the number of partners infected and the village HIV prevalence at baseline (here, year 3) are selected as the adjustment variable for the outcome regression in 58% and 18% of the trials, respectively.
For the joint effect of high coverage of both testand-treat and PrEP on the 7-year incidence from study start to termination, there is a notable impact of the trial design. Recall the test-and-treat control arm in Design 1 provides lower coverage of antiretroviral therapy for the trial duration, whereas the test-and-treat control arm for Design 2 provides lower coverage for years 0-3 and then scales up to high coverage. As a result, there is a larger joint effect of each test-and-treat and PrEP strategy combination in Design 1 than in Design 2. Indeed, the joint effect ranges from -7.3% to -8.8% in Design 1 and from -4.5% to -6.1% in Design 2. The basis for estimation of these effects involves 24 villages in Design 1 and only 16 in Design 2 (Table 1) . As a consequence, we are well-powered to detect these Table 2 ). Again, targeted estimation tends to provide a lower meansquared error and always yields more power than does the unadjusted. Throughout, confidence interval coverage is near or above nominal rate of 95%.
Discussion
We propose four strategies to target PrEP and study their impact within an ongoing test-and-treat trial. Our strategies range from simple (On-demand) to harnessing information in the underlying sexual network (Ring). We propose two modifications to the ongoing trials in response to the WHO's recommendations and the evolving landscape of HIV prevention and treatment. Investigators may favor one design over the other depending on resource constraints and their primary scientific questions.
To study the PrEP strategies and these designs, we simulate underlying sexual networks using a degreecorrected stochastic block model. While this network generation is highly idealized, it allows us to investigate the spread of epidemics across networks and the use of network information to target interventions and to improve the analysis. We simulate the infectious process within each village (network) using an agent-based compartmental model. Our epidemic model could be more closely calibrated to specific settings (e.g. accounting for variability in viral load evolution over time and its impact on transmission). [59] [60] [61] [62] Nonetheless, our idealized models capture the stochastic variation inherent in epidemics occurring on networks 63 and provide a framework for investigating pressing questions in HIV prevention and treatment. For estimation and inference, we compare the unadjusted estimator to a new targeted maximum likelihood estimator, dataadaptively adjusting for baseline covariates measured at both the individual and cluster levels. The latter consistently leads to notable gains in attained power, while maintaining nominal confidence interval coverage.
There are several areas of future work. First, we focus on trials where universal test-and-treat was randomized to the study villages in a parallel design. This work can be adopted to other common designs, such as stepped wedge and pair-matched trials. We also study a high prevalence setting wherein an average of 25% of village members were infected at baseline. Future studies will examine a lower prevalence setting; we suspect that impact of test-and-treat and PrEP will vary by context. Finally, we focused on estimation and inference of the sample average treatment effects on the village-level outcome (cumulative HIV incidence). There are many other interesting causal parameters, such as the effect on the individual-level outcome. Nonetheless, the implemented targeted maximum likelihood estimator is able to make full use of the individual-level data and could also easily accommodate additional complications due to right-censoring and informative dropout. 39, 57, 58 Overall, our work suggests that nesting a PrEP study within an ongoing universal test-and-treat trial will answer timely questions in HIV prevention and treatment as well as lead to combined effects greater than those of test-and-treat alone. While the impact of PrEP varied by test-and-treat intervention arm, offering PrEP to HIV-partners in serodiscordant couples consistently led to the greatest reductions in incidence.
